sierra health and life Radiation Therapy Coverage Update

Coverage Criteria — Fractionation, IGRT, and Special Radiation Services

Bone Metastases

Covered when ANY of the following for palliative EBRT to bone metastasis:

Palliative bone EBRT fractionation: Delivery of up to 10 fractions of radiation therapy is medically necessary; delivery of greater than 10 fractions is medically necessary for treatment of a site that has previously received radiation therapy.<=10 fractions or >10 if prior RT

Re-irradiation exception

Breast Adenocarcinoma

Covered when ALL of the following for EBRT for breast adenocarcinoma:

Breast EBRT fractionation options: Delivery of up to 5 fractions for accelerated partial breast irradiation (APBI) OR delivery of up to 21 fractions (inclusive of a boost to the tumor bed) OR delivery of up to 33 fractions (inclusive of a boost to the tumor bed) when any of the following apply: treatment of supraclavicular and/or internal mammary lymph nodes; post-mastectomy radiation therapy; prior thoracic radiation therapy; or connective tissue disorder (e.g., lupus, scleroderma).<=5 OR <=21 OR <=33 with specified conditions

33-fraction allowance limited to listed criteria

Not medically necessary: Delivery of greater than 33 fractions (inclusive of a boost to the tumor bed) for breast cancer is not medically necessary.>33 fractions

Explicit upper limit

Locally Advanced Non-Small Cell Lung Cancer

Covered when ALL of the following for locally advanced non-small cell lung cancer (with or without chemotherapy):

NSCLC fractionation: Delivery of up to 35 fractions is medically necessary.<=35 fractions

Delivery of greater than 35 fractions is not medically necessary.

Prostate Adenocarcinoma

Covered when ALL of the following for prostate adenocarcinoma EBRT:

Prostate EBRT fractionation options: Delivery of up to 20 fractions for definitive treatment in an individual with limited metastatic disease OR delivery of up to 28 fractions for localized prostate cancer OR delivery of up to 45 fractions for localized prostate cancer when any of the following apply: treatment to pelvic lymph nodes for high‑risk disease, post‑prostatectomy radiation therapy, history of inflammatory bowel disease (e.g., ulcerative colitis, Crohn's), or prior pelvic radiation therapy.<=20 OR <=28 OR <=45 with specified conditions

45-fraction allowance limited to listed criteria

Not medically necessary: Delivery of greater than 45 fractions for localized prostate cancer is not medically necessary.>45 fractions

Explicit upper limit

Image-Guided Radiation Therapy (IGRT)

IGRT is medically necessary under any of the following circumstances:

IGRT indications: When used with IMRT or proton beam radiation therapy (PBRT); when the target has received prior radiation or abuts a previously irradiated area; when implanted fiducial markers are used for target localization; or during definitive treatment using 3D-CRT for specified disease sites/conditions (including but not limited to APBI, breast boost with photons, hypofractionated whole-breast up to 5 fractions, prone breast treatments, left-breast with DIBH, boost for rectal or bladder cancer, esophageal, gastric, head and neck, hepatobiliary, lung, pancreatic, and soft tissue sarcoma).clinical indications as listed

Extensive list of guideline-supported indications

Documentation-based IGRT indication: IGRT with 3D-CRT may be medically necessary when documentation shows clinically significant normal tissue sparing with DIBH versus free breathing, inability to tolerate immobilization during CT simulation, significant target motion on imaging, or need for smaller CTV margins than traditionally used.documentation provided

Case-specific documentation required

Palliative radiation for symptomatic bone metastases (initial treatment and re-irradiation)

Covered when treatment aligns with guideline‑recommended dose‑fractionation and clinical context.

Conventional palliative EBRT regimens (initial treatment): Conventional palliative regimens recommended include 800 cGy in 1 fraction; 2000 cGy in 5 fractions; 2400 cGy in 6 fractions; or 3000 cGy in 10 fractions for symptomatic bone metastases (strong recommendation, high-quality evidence).examples as listed

ASTRO guideline summary

Re-irradiation regimens: For re-irradiation to the same site, recommended regimens include 800 cGy in 1 fraction; 2000 cGy in 5 fractions; 2400 cGy in 6 fractions; or 2000 cGy in 8 fractions (strong recommendation, moderate-quality evidence).examples as listed

ASTRO guideline summary

SBRT consideration: SBRT (single or multiple fraction) may have a slightly to moderately higher likelihood of pain response versus multiple-fraction EBRT in some studies; consider SBRT when clinically appropriate accounting for prior RT and normal tissue constraints.

Adjuvant radiation options for early-stage breast cancer

Covered when patient selection matches evidence from randomized trials supporting PBI or hypofractionation.

Partial-breast irradiation (PBI): PBI (including 3D-CRT, IMRT, brachytherapy) demonstrates similar ipsilateral breast recurrence and overall survival at 5–10 years compared with WBI in appropriately selected patients; IORT was associated with higher ipsilateral breast recurrence in multiple studies.appropriate selection per trials

AHRQ systematic review

Five-fraction whole-breast regimens: A 5-fraction schedule (e.g., 26–27 Gy in 5 fractions over one week) is non-inferior to 40 Gy in 15 fractions for local control in selected patients; trials used verification imaging per fraction with correction of displacements.verification imaging per trial

Brunt et al. trial

Hypofractionated WBI (e.g., 40 Gy in 15 fractions or 42.5 Gy in 16 fractions) shows less acute toxicity and similar long-term control versus conventional fractionation and is appropriate per patient factors and guidelines.

Breast: HF-WBI / APBI coverage

Breast cancer: covered when ALL of the following are met

Breast HF-WBI / APBI eligibility: Patients with early-stage invasive breast cancer after breast-conserving surgery or DCIS may receive hypofractionated whole-breast irradiation (e.g., 40 Gy in 15 fractions or 42.5 Gy in 16 fractions) or partial-breast regimens (e.g., 30 Gy in 5 fractions) per guideline-recommended indications; use verification imaging and document target volumes and any cardiac‑sparing technique (e.g., DIBH) when selected.per guideline dose-fractionation

Supported by randomized trials and ASTRO/NCCN/NICE recommendations

NSCLC: definitive chemoradiation coverage

Locally advanced NSCLC: covered when ALL of the following are met

Definitive chemoradiation dosing: Patients with unresectable stage III NSCLC receiving curative-intent chemoradiation should receive standard-dose radiotherapy (60 Gy in 2 Gy daily fractions over ~6 weeks) with concurrent chemotherapy; dose escalation to 74 Gy with concurrent chemotherapy is not supported and was associated with worse overall survival.standard 60 Gy in 2 Gy fractions

Based on RTOG/NRG trial and ASTRO guidance

Prostate: hypofractionation and pelvic nodal coverage

Prostate cancer: covered when ALL of the following are met

Localized prostate RT fractionation: For localized prostate adenocarcinoma, moderate hypofractionated EBRT (examples: 60 Gy in 20 fractions) is an acceptable alternative to conventional fractionation for low‑ and intermediate‑risk patients and selected high‑risk patients when pelvic nodes are not treated; when pelvic nodes are treated, document nodal risk (e.g., ≥20%) and intent and consider whole‑pelvic approaches per evidence.per guideline regimens

Supported by randomized trials (Catton, Dearnaley) and ASTRO/NCCN guidance

WPRT for high-risk prostate: Prophylactic whole-pelvic radiotherapy may be considered for patients with estimated nodal risk ≥20% to improve biochemical failure‑free survival; discuss that overall survival benefit has not been shown.nodal risk >= 20%

Murthy et al.

Hypofractionated EBRT (prostate)

Covered when meeting professional guideline–supported indications and delivery standards:

Prostate hypofractionation coverage: Patient has localized low‑ or intermediate‑risk prostate cancer OR selected high‑risk patients when pelvic nodes will not be treated; AND treatment uses a guideline‑recommended moderate hypofractionation regimen (examples: 3 Gy × 20; 2.7 Gy × 26; 2.5 Gy × 28); AND image‑guidance and appropriate immobilization/advanced planning (IMRT/IGRT) are used to ensure target localization and normal tissue protection.per guideline regimens

ASTRO/AUA/NCCN recommendations referenced

IGRT requirements for high-precision RT

Covered when ALL of the following apply:

IGRT use for conformal or hypofractionated treatments: Treatment is delivered with modalities where geometric accuracy materially affects outcomes (e.g., IMRT, SBRT, proton therapy, 3D‑CRT with tight margins, re‑irradiation, pelvic node irradiation, or dose‑escalated regimens); AND daily or high‑frequency volumetric image guidance (CBCT/MVCT/4D‑IG) is implemented per site‑specific standards; AND documented QA and CT‑based image‑guidance quality control procedures are in place (including daily QC when PTV margins are tight).daily/high‑frequency IGRT and QA documented

AAPM and ACR‑ASTRO practice parameters support daily QC and IGRT for high‑precision treatments

Clinical Indications for IGRT

IGRT is indicated or recommended in situations where accuracy and motion management are critical; covered when ALL of the following apply:

Indication and rationale: Target volume located near or within critical structures OR target subject to daily internal motion OR narrow margins required to protect adjacent structures OR adjacent previously irradiated tissues requiring precise abutting fields OR planned dose escalation beyond usual doses.clinical indication present

Based on ACR‑ASTRO and ASTRO guidance

Techniques: Use of IGRT modalities (orthogonal planar imaging, volumetric CBCT/MVCT, CT‑based onboard imaging) and motion management strategies (respiratory gating, tumor tracking, abdominal compression, DIBH, full bladder protocols) as appropriate to site and technique.technique‑appropriate

Examples provided in guidelines

Site-Specific Recommendations

Site- and technique-specific recommendations (examples):

Liver and hepatic tumors: Daily image guidance and respiratory motion management are recommended for dose‑escalated hypofractionated EBRT for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.dose‑escalated hypofractionation

ASTRO guideline

Oligometastatic NSCLC / SABR/SBRT: Image guidance and appropriate motion management are recommended when using highly conformal RT with inverse planning and steep dose gradients (e.g., SABR/SBRT for oligometastatic lung lesions).highly conformal with steep gradients

ASTRO/NCCN guidance

Head and neck: Image guidance is required to ensure accurate daily delivery; repeat imaging and replanning may be needed for significant anatomical changes.

Quality and Safety Criteria

Quality, safety, and resource considerations:

QA and staffing: IGRT implementation requires an interdisciplinary team of trained specialists, sufficient personnel resources, specialized technology, documented standard operating procedures, and a comprehensive QA program with daily quality control records and allowance of adequate time for QA checks and troubleshooting.documented QA program and staffing

ASTRO safety white paper and AAPM/ACR‑ASTRO practice parameters

When the IGRT criteria in this policy are not satisfied, image-guided radiation therapy is considered not medically necessary. Examples specifically cited in the policy include superficial treatment of skin cancer (including superficial radiation therapy or electronic brachytherapy) and use of image guidance solely to align bony landmarks without implanted fiducials (for example, during palliative radiation therapy). These scenarios do not meet the listed indications where IGRT meaningfully improves geometric accuracy or clinical outcomes and therefore are exclusionary for IGRT coverage.

Absent documentation showing one of the policy’s listed indications (e.g., use with IMRT or PBRT, implanted fiducials, prior irradiation to the target, requirement for narrow margins, clinically significant normal-tissue sparing with DIBH, or significant target motion on imaging), IGRT should not be authorized.

Systematic review evidence summarized in the policy found that partial breast irradiation (PBI) modalities generally produced similar ipsilateral breast recurrence and overall survival compared with whole-breast irradiation (WBI) in appropriately selected patients, but intraoperative radiotherapy (IORT) was associated with higher ipsilateral breast recurrence at five and 10 years. Selection of IORT for PBI should therefore account for this increased local-recurrence risk compared with WBI and alternative PBI techniques supported by the evidence.

The policy therefore notes IORT’s higher ipsilateral recurrence signal relative to WBI in the AHRQ/Shumway et al. review and recommends careful patient selection when considering IORT as a PBI approach.

Randomized trial evidence cited in the policy (RTOG/NRG study) showed that escalation of dose to 74 Gy given with concurrent chemotherapy for unresectable stage III NSCLC did not improve outcomes and was associated with greater toxicity; the authors concluded the 74 Gy regimen was not superior and might be harmful compared with the standard 60 Gy in 2 Gy fractions. Consequently, the policy recommends against dose escalation to 74 Gy with concurrent chemotherapy because of the association with worse overall survival and potential harm.

The policy highlights that curative-intent chemoradiation for stage III NSCLC should follow the standard-dose approach and avoid unsupported dose escalation that has demonstrated inferior survival.

For reirradiation of gynecologic recurrences using three-dimensional image-guided brachytherapy (3D‑IGBT), the policy summarizes a systematic review showing highly variable outcomes and a wide range of late grade ≥3 toxicities across studies. Local control rates varied (roughly 44%–71%), overall survival outcomes were heterogeneous, and grade ≥3 toxicity rates ranged from low to very high in some reports; one study even reported a grade 5 event. The review authors concluded that while 3D‑IGBT can be a feasible salvage option in select, inoperable patients, the heterogeneity of small studies means that dose constraints and recommended doses for optimal local control are not established, and high late toxicity is a meaningful concern.

Because the evidence does not define consistent dose recommendations or organ-at-risk constraints, broad coverage recommendations for 3D‑IGBT reirradiation in gynecologic disease are limited and require individualized multidisciplinary justification.

Professional guidance cited in the policy specifies that IGRT is not indicated for certain situations, including superficial skin cancer treatment and when imaging would be used only to align bony landmarks without implanted fiducials. ASTRO’s coding resource explicitly lists these circumstances as examples where IGRT is not appropriate because the technology does not materially change target localization or clinical management.

Providers should not request or expect IGRT coverage for superficial treatments or for simple bony alignment during palliative courses unless documentation demonstrates an applicable indication from the policy’s IGRT criteria.

The policy specifies that delivery of greater than 33 fractions (inclusive of any boost to the tumor bed) for breast cancer is not medically necessary. This explicit upper limit applies when providing EBRT for breast adenocarcinoma and is intended to bound conventional and hypofractionated regimens; exceptions allowing up to 33 fractions are already described for select clinical situations, but treatment exceeding 33 fractions is outside the policy’s coverage criteria.

For locally advanced non‑small cell lung cancer treated with EBRT (with or without chemotherapy), the policy states that delivery of greater than 35 fractions is not medically necessary. Authorization should therefore reflect an upper limit of 35 fractions for standard definitive chemoradiation regimens unless a documented, guideline-supported exception applies.

When providing EBRT for localized prostate cancer the policy sets an explicit upper limit: delivery of greater than 45 fractions is not medically necessary. The policy allows up to 28 fractions for standard localized treatment and up to 45 fractions only in specific circumstances (e.g., pelvic nodal irradiation, post‑prostatectomy RT, prior pelvic RT, or inflammatory bowel disease); beyond 45 fractions is outside the covered criteria.

The evidence summarized for palliative bone radiation shows that both single‑fraction and multi‑fraction regimens provide similar short‑term pain relief, with single‑fraction schedules having lower acute toxicity but higher retreatment rates. The policy therefore does not impose an absolute non‑coverage statement favoring one approach; instead, it recognizes that fractionation choice is context-dependent and should be informed by prognosis, prior RT, expected re‑irradiation risk, and patient goals.

Because randomized trials (for example, Hartsell et al.) demonstrated equivalent pain and narcotic relief at three months between 8 Gy ×1 and 30 Gy ×10, the policy supports clinical selection of single‑versus multi‑fraction regimens rather than declaring one universally not medically necessary.

The policy reiterates that evidence from a randomized trial comparing 74 Gy versus 60 Gy with concurrent chemotherapy in stage III NSCLC showed no benefit and suggested harm with the higher dose; specifically, esophagitis and other toxicities were more common and overall survival was not improved. Accordingly, the policy underscores that 74 Gy delivered with concurrent chemotherapy was associated with inferior survival and should not be used outside of supported indications or clinical trials.

This additional caution reinforces that high‑dose escalation (74 Gy) in combination with concurrent chemotherapy is contraindicated by the cited trial results.

When evidence for reirradiation is heterogeneous, dose constraints are unclear, and studies report substantial late toxicity, the policy recommends individualized clinical judgment and multidisciplinary decision‑making. For gynecologic reirradiation with 3D‑IGBT—where outcomes and toxicities varied and optimal doses/constraints were not established—the policy advises that treatment decisions be made after careful multidisciplinary review and documented justification, rather than applying broad coverage.

In practice this means authorization for reirradiation in such settings should include detailed documentation of expected benefits, prior dose records, planned doses and constraints, and multidisciplinary consensus supporting the treatment approach.

The policy includes FDA approval information for radiation therapy devices for informational purposes only and explicitly states that FDA approval alone is not a basis for coverage. Although device approvals (e.g., for accelerators, IMRT/SBRT/SRS equipment, proton delivery systems) are noted, the policy clarifies that such approvals do not determine medical necessity or guarantee coverage decisions.

Coverage determinations remain based on the clinical criteria and evidence summarized in the policy rather than device regulatory status.

Coding — Applicable and Removed Procedure Codes

Referenced CPT and proton delivery codesCPT

77331	Special dosimetry (e.g., TLD, microdosimetry) (specify)
77370	Special medical radiation physics consultation
77387	Guidance for localization of target volume for delivery of radiation treatment, includes intrafraction tracking, when performed
77399	Unlisted procedure, medical radiation physics, dosimetry and treatment devices, and special services
77402	Radiation treatment delivery; Level 1, including imaging guidance, when performed
77407	Radiation treatment delivery; Level 2, single-isocenter, including imaging guidance, when performed
77412	Radiation treatment delivery; Level 3, multiple isocenters or single-isocenter with active motion management, including imaging guidance, when performed
77436	Surface radiation therapy; superficial or orthovoltage, treatment planning and simulation-aided field setting
77437	Surface radiation therapy; superficial, delivery, 150 kV, per fraction
77438	Surface radiation therapy; orthovoltage, delivery, >150-500 kV, per fraction

1–10 of 15

1/2

No explicit CPT/HCPCS/ICD codes in this fragmentmixed

No codes listed

Fractionation regimens referencedmixed

n/a	Document lists fractionation regimens (3 Gy × 20, 2.7 Gy × 26, 2.5 Gy × 28) rather than billing codes.

Updated Applicable CPT/HCPCS CodesCPT

77436	Replaced 77401 with 77436 (per policy history)
77437	Replaced 77401 with 77437 (per policy history)
77438	Replaced 77401 with 77438 (per policy history)
77439	Replaced 77401 with 77439 (per policy history)
77402	Description replaced (per policy history)
77407	Description replaced (per policy history)
77412	Description replaced (per policy history)

Removed CodesmixedNot Covered

77014	Removed from applicable list (per policy history)
77835	Removed from applicable list (per policy history)
77836	Removed from applicable list (per policy history)
G6001-G6017	Multiple G‑codes removed from applicable list (per policy history)

inv-33: Dose-fractionation thresholds — Examples for WBI, APBI, NSCLC definitive dosing

Whole-breast hypofractionation (HF‑WBI)Typical preferred schedules: 40–42.5 Gy delivered in 15–16 fractions (ASTRO/NCCN preferred).

Accelerated partial breast irradiation (APBI)Preferred APBI regimen: 30 Gy in 5 fractions (NCCN).

Definitive NSCLC chemoradiationStandard curative-intent dose: 60 Gy given as 2 Gy per fraction (60 Gy/30 fx).

Prostate definitive hypofractionation exampleNon-inferior moderate hypofractionated example: 60 Gy in 20 fractions (per randomized trials).

Upper-fraction limits (policy guidance)Examples of policy fractionation caps: breast regimens up to 33 fractions (with conditions); NSCLC up to 35 fractions; localized prostate up to 28 fractions (unless specific indications permit more).

Provider Actions — Prior Authorization, Documentation, and QA

Billing Rule

Coding reference and prior authorization implication

Applicable CPT/HCPCS/diagnosis codes are provided for reference only and do not guarantee coverage; use current, updated codes when requesting prior authorization and billing. Claims submitted with removed or outdated CPT/HCPCS codes may be denied. When requesting prior authorization, include the specific codes to be performed and verify member-specific benefit coverage.

Use updated CPT/HCPCS codes for prior authorization and claims submission.
Listing of a code in this policy does not imply coverage or reimbursement.

Prior Authorization

Conventional palliative RT regimens for bone metastases

For conventional palliative EBRT to bone metastases, document the selected regimen and rationale. Recommended conventional schedules include single-fraction 800 cGy (8 Gy), 2000 cGy in 5 fractions, 2400 cGy in 6 fractions, and 3000 cGy in 10 fractions. For spine metastases with cord compression or when re-irradiation is planned, follow guideline-recommended fractionation and document prior RT dose. Re-irradiation to a previously treated site may justify delivering greater than 10 fractions; clearly document prior treatment details.

Background and Evidence Summary

External‑beam radiation therapy (EBRT) encompasses modalities such as three‑dimensional conformal radiation therapy (3D‑CRT), intensity‑modulated radiation therapy (IMRT), and proton beam radiation therapy (PBRT); these techniques are commonly used to treat cancer and may require advanced planning and verification to ensure accurate delivery. Image‑guided radiation therapy (IGRT) refers to the use of CT‑based or volumetric imaging (for example, cone‑beam CT or MVCT) during simulation and treatment to detect and correct patient and target positional uncertainties and thereby improve geometric accuracy of delivery.

Professional practice documents (AAPM, ACR‑ASTRO, ASTRO) emphasize that IGRT and comprehensive QA programs are recommended when geometric accuracy materially affects outcomes, such as with IMRT, PBRT, SBRT, reirradiation, pelvic node irradiation, or dose‑escalated regimens; IGRT implementation requires an interdisciplinary team, documented QA, and routine quality control to support safe, precise treatment.

Definitions and Terminology

inv-57: Definitive Treatment — definition

DefinitionRadiation treatments delivered with curative intent to eradicate cancer (Definitive Treatment).

Clinical intentTypically encompasses regimens and doses intended to achieve long-term disease control or cure rather than palliation.

Contextual useApplied to site‑specific definitive regimens (e.g., prostate, NSCLC) described elsewhere in the policy.

inv-58: Limited Metastatic Disease — definition (prostate-specific limits noted)

Definition (prostate-specific)Limited Metastatic Disease: absence of visceral metastasis or fewer than four bone metastases with no metastasis outside vertebral bodies or pelvis.

ApplicabilityThis definition is applied to prostate cancer scenarios where limited metastatic burden permits consideration of definitive or intensified local therapy.

OpenPayer

Fractionation, Image-Guidance, and Special Radiation Services

Coverage Criteria — Fractionation, IGRT, and Special Radiation Services

Coding — Applicable and Removed Procedure Codes

Provider Actions — Prior Authorization, Documentation, and QA

Background and Evidence Summary

Definitions and Terminology